Fintel reports that on January 16, 2025, Cantor Fitzgerald initiated coverage of NICE - Depositary Receipt () (NasdaqGS:NICE) ...

Fintel reports that on January 16, 2025, Cantor Fitzgerald initiated coverage of MongoDB (NasdaqGM:MDB) with a Overweight ...

Analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a ...

Analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for Nova in a report issued on Monday, January 13th. Cantor Fitzgerald analyst M. Prisco forecasts that the semiconductor ...

There is no Morningstar’s Analysis data available. We sell different types of products and services to both investment professionals and individual investors. These products and services are ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) on January 14 and set a price ...

Cantor Fitzgerald is charged with violating antifraud and proxy provisions. Former Comtech CEO is charged with insider trading ahead of negative earnings. The Securities and Exchange Commission on ...

Cantor Fitzgerald initiated coverage of Zoom Communications (ZM) with a Neutral rating and $87 price target Stay Ahead of the Market:Discover ...

Wall Street brokerage Cantor Fitzgerald has agreed to pay a $6.75-million penalty to settle Securities and Exchange Commission charges that it misled investors in blank-check companies it ...

Cantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The most substantial contributor to the rating is the parent firm's five-year risk-adjusted success ratio of 90%.